Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver

References

• ANDERSSON, T., MINERS, J. O., VERONESE, M. E. and BIRKETT, D. J., 1994, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 131–137.
   PubMed Web of Science ®Google Scholar
• Bomuuk, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   PubMedGoogle Scholar
• BOXENBAUM, H., 1980, Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokine tics and Biopharnzaceutics, 8, 165–176.
   PubMedGoogle Scholar
• BRIAN, W. R., SARI, M. A., IWASAKI, M., SHIMADA, T., KAMINSKY, L. S. and GUENGERICH, F. P., 1990, Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry, 29, 11280–11292.
   PubMed Web of Science ®Google Scholar
• BRIAN, W. R., SRIVASTAVA, P. K., UMBENHAUER, D. R., LLOYD, R. S. and GUENGERICH, F. P., 1989, Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry, 28, 4993–4999.
   PubMed Web of Science ®Google Scholar
• CHANG, T. K. H., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacethyloleandomycin, a-naphthofiavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437–442.
   Google Scholar
• EAGLING, V. A., TIIA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107–114.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., Kim, D. H. and Iwasmti, M., 1991, Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168–179.
   PubMed Web of Science ®Google Scholar
• INABA, T., JuRimA, M., MAHON, W. A. and KALow, W., 1985, In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metabolism and Disposition, 13, 443–448.
   PubMed Web of Science ®Google Scholar
• ISHIHARA, K., KOMURO, Y., NISHIYAMA, N., YAMASAKI, K. and HOTTA, K., 1992, Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittel-ForschunglDrug Research, 42, 1462–1466.
   PubMed Web of Science ®Google Scholar
• IWATSUBO, T., HIROTA, N., O.1E, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147–171.
   Google Scholar
• Kisiti, S. and OGAWA, N., 1989, Phase I clinical study of the anti-ulcer drug proamipide (OPC-12759). Journal of Adult Diseases, 19, 355–363.
   Google Scholar
• KLEINE, A., KLUGE, S. and PESKAR, B. M., 1993, Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Digestive Diseases and Sciences, 38, 1441–1449.
   PubMed Web of Science ®Google Scholar
• KRONBACH, T., MATHYS, D., GUT, J., CATIN, T. and MEYER, U. A., 1987, High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O.demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Analytical Biochemistry, 162, 24–32.
   PubMedGoogle Scholar
• KUNZE, K. L. and TRAGER, W. F., 1993, Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chemical Research in Toxicology, 6, 649–656.
   PubMed Web of Science ®Google Scholar
• LEEMANN, T., TRANSON, C. and DAYER, P., 1993, Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. _Life Sciences, 52, 29–34.
   PubMed Web of Science ®Google Scholar
• MINERS, J. O., COULTER, S., TUKEY, R. H., VERONESE, M. E. and BIRKETT, D. J., 1996, Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O.demethylation of R- and S-naproxen. Biochemical Pharmacology, 51, 1003–1008.
   PubMed Web of Science ®Google Scholar
• OTTON, S. V., GILLAM, E. M. J., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1990, Propranolol oxidation by human liver microsomes — the use of cumene hydroperoxide to probe isoenzymes specificity and regio- and stereoselectivity. British Journal of Clinical Pharmacology, 30, 751–760.
   Google Scholar
• PETER, R., BOCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. and YANG, C. S., 1990, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P45011E1. Chemical Research in Toxicology, 3, 566–573.
   PubMed Web of Science ®Google Scholar
• RELLING, M. V., AOYAMA, T., GONZALEZ, F. J. and MEYER, U. A., 1990, Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. Journal of Pharmacology and Experimental Therapeutics, 252, 442–447.
   PubMed Web of Science ®Google Scholar
• RETTIE, A. E., KORZEKWA, K. R., KUNZE, K. L., LAWRENCE, R. F., EDDY, A. C., ÄOYAMA, T., GELBOIN, H. V., GONZALEZ, F. J. and TRAGER, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chemical Research in Toxicology, 5, 54–59.
   Google Scholar
• RODRIGUES, A. D., KuituutA, M. J., ROBERTS, E. M., OUELLET, D. and RODGERS, T. R., 1996, [0-Methyl naproxen O.demethylase activity in human liver microsomes: Evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metabolism and Disposition, 24, 126–136.
   PubMed Web of Science ®Google Scholar
• SESARDIC, D., Booms, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. and DAVIES, D. S., 1990, Furafylline in a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology, 29, 651–663.
   PubMed Web of Science ®Google Scholar
• SHIOYA, Y., KASHIYAMA, E., OKADA, K., KUSUMOTO, N., ABE, Y., UCHIDA, M. and SHIMIZU, T., 1989, Metabolic fate of the anti-ulcer agent, (±)-2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid (OPC-12759) — absorption, distribution and excretion in rats and dogs. Iyakuhin Kenkyu, 20, 522–533.
   Google Scholar
• UCHIDA, M., TABUSA, F., KOMATSU, M., MORITA, S., KANBE, T. and NAKAGAWA, K., 1986, Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. Synthesis and antiulcer activity ofthe metabolites of 2- (4- chlorobenzoylamino) -3 - [2(1H)- quinolinon-4-yl] propionic acid.Chemical and Pharmaceutical Bulletin, 34, 4821–4824.
   PubMed Web of Science ®Google Scholar
• WALLANCE, J. L., 1994, The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage — potential for development of gastrointestinal tract safe NSAIDs. Canadian Journal of Physiology and Pharmacology, 72, 1493–1498.
   PubMedGoogle Scholar
• WAXMAN, D. J., ATTISANO, C., OUENGERICH, F. P. and LAPENSON, D. P., 1988, Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 60-hydroxylase cytochrome P-450 enzyme. Archives of Biochemistry and Biophysics, 263, 424–436.
   PubMed Web of Science ®Google Scholar
• WIENKERS, L. C., WURDEN, C. J., STORCH, E., KUNZE, K. L., BETTIE, A. E. and TRAGER, W. F., 1996, Formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metabolism and Disposition, 24, 610–614.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. and VANDENBRANDEN, M., 1993, Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Archives of Biochemistry and Biophysics, 306, 240–245.
   PubMed Web of Science ®Google Scholar
• YAMASAKI, K., ISHIYAMA, H., Immzumi, T., KANBE, T. and YABUUCHI, Y., 1989, Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Japanese Journal of Pharmacology, 49, 441–448.
   PubMedGoogle Scholar
• YAMASAKI, K., KANBE, T., CHIJIWA, T., ISHIYAMA, H. and MORITA, S., 1987, Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. European Journal of Pharmacology, 142, 23–29.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA, T., NAITO, Y., NAKAMURA, S., NISHIMURA, S., KANEKO, T., IiNumA, S., TAKAHASHI, S., KONDO, M. and YAMASAKI, K., 1993a, Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indomethacin in rats. Arzneimittel-ForschunglDrug Research, 43, 1327–1330.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA, T., NAITO, Y., TANIGAWA, T. and KONDO, M., 1993b, Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittel-Forschungl Drug Research, 43, 363–366.
   PubMed Web of Science ®Google Scholar